17.07.2024, 4911 Zeichen

Aachen, Germany (OTS) - Grünenthal, a leading pharmaceutical company specializing in pain research and management, has announced significant investments in its Latin American production sites. These investments will enhance Grünenthal's production network, ensuring a reliable supply of medicines for patients across Latin America, Europe, and beyond.
Investment of more than €80 million to modernise Latin American production sites.\nIn Santiago de Chile, a 3,500-square-metre solids plant has been completely refurbished, creating a world-class manufacturing facility with a production capacity of 1.8 billion tablets annually.\nIn Quito, Ecuador, a new 1,800-square-metre plant will enable the production of 300 million high-quality tablets annually for pain patients in 17 European countries.\n Grünenthal operates a robust production network with five manufacturing sites in Germany, Switzerland, Italy, Chile, and Ecuador. These sites produce medicine from Grünenthal's portfolio and offer contract manufacturing services to third parties. Grünenthal recently invested over €80 million to enhance its production capabilities in Latin America. To ensure production excellence and expand the geographical reach of its Latin American facilities, Grünenthal is implementing a standardized approach to product robustness, quality, and regulatory compliance across all its global manufacturing sites.
"Our investment in Latin America is a strong demonstration of our commitment to long-term competitiveness in the region,” says Victor Barbosa, Head of Global Operations and member of the Executive Board Team. "Future-proofing our manufacturing capabilities underscores our commitment to ensuring a safe, reliable, and efficient supply of medicine to patients globally. Grünenthal delivers high-quality medicine from Latin America to the world—a unique capability in the region.“
Grünenthal has been operating in Santiago de Chile for 45 years. The company’s largest manufacturing investment in the past three decades, a new 3,500-square-meter facility in Chile, will enable a production capacity of up to 1.8 billion tablets annually. This facility's state-of-the-art technology reinforces Grünenthal's position as Chile's leading pharmaceutical manufacturer. Additionally, the advanced technology will positively impact employees by providing training and specialization, positioning them at the forefront of the industry. Grünenthal aims to complete the certification process with the European Medicines Agency (EMA) by November 2025, enabling the supply of medicines from Chile to Europe.
Grünenthal's manufacturing site in Quito, Ecuador, is one of the few in Latin America licensed to export to Europe and the only one in Ecuador with an EU Good Manufacturing Practice certificate, setting a high industry standard. The 50,000-square-metre campus is Ecuador's largest and most modern manufacturing plant for solid, semi-solid, and liquid pharmaceuticals. Starting in 2025, the new facility will produce up to 300 million high-quality tablets annually for pain patients in 17 European countries.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.
More information: https://www.grunenthal.com (https://www.grunenthal.com) and [Grünenthal Report 2023/24] (https://grunenthal-annualreport23.corporate-report.net/#0)
Follow us on:
LinkedIn: [Grünenthal Group] (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fww w.linkedin.com%2Fcompany%2Fgruenenthal%3ForiginalSubdomain%3Dde&data= 05%7C02%7CAlexandra.Paesch%40grunenthal.com%7C148c5efb478543e5a69f08d c4ca678ad%7C1aa3f19739d54269bcea93372aa086d9%7C0%7C0%7C63846952507246 3320%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJB TiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=SrmoYmZOKJUHShIZzqjf2vI iqyrf5AT%2BxR924ZoSlfY%3D&reserved=0)
Instagram: [Grünenthal] (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fww w.instagram.com%2Fgrunenthal%2F%3Fhl%3Dde&data=05%7C02%7CAlexandra.Pa esch%40grunenthal.com%7C148c5efb478543e5a69f08dc4ca678ad%7C1aa3f19739 d54269bcea93372aa086d9%7C0%7C0%7C638469525072478288%7CUnknown%7CTWFpb GZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn 0%3D%7C0%7C%7C%7C&sdata=O6riBAbMgpBu%2FRebEJkGl3c8h6hFk%2Bskpb%2FxUkG uDFw%3D&reserved=0)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #695: Einschätzung zu Addikos Aufstieg in der ATX-Beobachtungsliste, EU-Fehler im Privatanlegerzugang

Aktien auf dem Radar:Amag, Zumtobel, RHI Magnesita, Austriacard Holdings AG, Warimpex, Flughafen Wien, Rosgix, Wienerberger, Porr, Verbund, Marinomed Biotech, Uniqa, Addiko Bank, Josef Manner & Comp. AG, S Immo, Wiener Privatbank, Oberbank AG Stamm, Agrana, CA Immo, Erste Group, EVN, Immofinanz, Österreichische Post, Telekom Austria, VIG, Palfinger, UnitedHealth, Zalando, Deutsche Bank, E.ON , RWE.

---

Mehr aktuelle OTS-Meldungen HIER